These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18308147)

  • 1. The medical treatment of inflammatory breast cancer.
    Dawood S; Ueno NT; Cristofanilli M
    Semin Oncol; 2008 Feb; 35(1):64-71. PubMed ID: 18308147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of locoregional therapy in inflammatory breast cancer.
    Woodward WA; Buchholz TA
    Semin Oncol; 2008 Feb; 35(1):78-86. PubMed ID: 18308149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary systemic chemotherapy for inflammatory breast cancer.
    Sinclair S; Swain SM
    Cancer; 2010 Jun; 116(11 Suppl):2821-8. PubMed ID: 20503414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of locally advanced and inflammatory carcinoma of the breast.
    Ackland SP; Bitran JD; Dowlatshahi K
    Surg Gynecol Obstet; 1985 Oct; 161(4):399-408. PubMed ID: 3901356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
    Palmieri C; Shah D; Krell J; Gojis O; Hogben K; Riddle P; Ahmad R; Tat T; Fox K; Porter A; Mahmoud S; Kirschke S; Shousha S; Gudi M; Coombes RC; Leonard R; Cleator S
    Clin Breast Cancer; 2011 Apr; 11(2):93-102. PubMed ID: 21569995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidating an uncommon disease: inflammatory breast cancer.
    Crane K
    J Natl Cancer Inst; 2011 Sep; 103(18):1358-60. PubMed ID: 21881039
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
    Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
    Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer.
    Montemurro F; Aglietta M
    Clin Breast Cancer; 2005 Apr; 6(1):77-80. PubMed ID: 15899075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of a patient with inflammatory breast cancer.
    Mason G
    Oncology (Williston Park); 2008 Jul; 22(8 Suppl Nurse Ed):29-32. PubMed ID: 19856568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico].
    Arce-Salinas C; Lara-Medina FU; Alvarado-Miranda A; Castañeda-Soto N; Bargalló-Rocha E; Ramírez-Ugalde MT; Pérez-Sánchez V; Rivera L; Gambo-Vignole C; Santamaría-Galicia J; Nieves-Casas RI; Morán-Muñoz H; Mohar-Betancourt A
    Rev Invest Clin; 2012; 64(1):9-16. PubMed ID: 22690524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
    Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neoadjuvant treatment of breast cancer: implications for the pathologist].
    Le Guellec S; Perallon R; Alunni JP; Charitansky H; Leaha C; Gonzalez AM; Chateau MC; Simony-Lafontaine J; Jacot W; Gutowski M; Penault-Llorca F; Dalenc F; Lacroix-Triki M
    Ann Pathol; 2011 Dec; 31(6):442-54. PubMed ID: 22172117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers].
    Liao N; Zhang GC; Li XR; Yao M; Wang K
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):943-5. PubMed ID: 19460715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.
    Mayer EL; Burstein HJ
    J Clin Oncol; 2008 Mar; 26(8):1198-200. PubMed ID: 18323544
    [No Abstract]   [Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for locally advanced breast cancer.
    Specht J; Gralow JR
    Semin Radiat Oncol; 2009 Oct; 19(4):222-8. PubMed ID: 19732686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer.
    Sánchez-Muñoz A; García-Tapiador AM; Dueñas-García R; Jaén-Morago A; Ortega-Granados AL; Martínez-Ortega E; Fernández Morales M; Fernández-Navarro M; de la Torre Cabrera C; Dueñas B; Ureña C; Martínez J; Morales F; Ramírez-Tortosa C; Sánchez-Rovira P
    Breast J; 2008; 14(5):506-7. PubMed ID: 18705667
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.